Cabaletta Bio, Inc.

NasdaqGS:CABA Stock Report

Market Cap: US$676.7m

Cabaletta Bio Past Earnings Performance

Past criteria checks 0/6

Cabaletta Bio's earnings have been declining at an average annual rate of -32.5%, while the Biotechs industry saw earnings growing at 30% annually.

Key information

-32.51%

Earnings growth rate

-9.29%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-149.80%
Net Marginn/a
Last Earnings Update31 Dec 2025

Recent past performance updates

No updates

Recent updates

Analysis Article • Mar 24

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 27

Cabaletta Bio: Do You Buy With The Insiders?

Summary Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA’s prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development. Strengths include promising pipeline updates, while risks remain around cash runway and clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Cabaletta Bio: Finding Optimism In Dire Straits

Summary Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches. With a market cap under $150 million, CABA's stock is a potential bargain if they achieve even partial success in their pipeline. Read the full article on Seeking Alpha
Analysis Article • Dec 10

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 22

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha
Analysis Article • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha
Analysis Article • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Analysis Article • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...
Analysis Article • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Analysis Article • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Analysis Article • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Analysis Article • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Revenue & Expenses Breakdown

How Cabaletta Bio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:CABA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 250-16830143
30 Sep 250-15931132
30 Jun 250-14431118
31 Mar 250-12730104
31 Dec 240-1162897
30 Sep 240-1042589
30 Jun 240-902477
31 Mar 240-772165
31 Dec 230-681955
30 Sep 230-621750
30 Jun 230-571645
31 Mar 230-561643
31 Dec 220-531539
30 Sep 220-511537
30 Jun 220-511537
31 Mar 220-501435
31 Dec 210-461432
30 Sep 210-421428
30 Jun 210-391326
31 Mar 210-361323
31 Dec 200-331321
30 Sep 200-291218
30 Jun 200-261116
31 Mar 200-21913
31 Dec 190-22711
30 Sep 190-19510
30 Jun 190-2349
31 Mar 190-2137
31 Dec 180-1224

Quality Earnings: CABA is currently unprofitable.

Growing Profit Margin: CABA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CABA is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.

Accelerating Growth: Unable to compare CABA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CABA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.2%).

Return on Equity

High ROE: CABA has a negative Return on Equity (-149.8%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/06 18:40
End of Day Share Price 2026/05/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cabaletta Bio, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI